8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)

144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

SCHEDULE 13G - GE HealthCare Technologies Inc. (0001932393) (Subject)

10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

SCHEDULE 13G - GE HealthCare Technologies Inc. (0001932393) (Subject)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

Issued on behalf of Aleen Inc. VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Last month marked a major turning point as Google launched Gemini 3[1], proving that new AI models can now outperform humans on critical tasks. At the same time, global regulators accelerated the shift[2] toward strict rules for AI in medical devices, signaling that the technology is finally ready for real-world commercial use. This rapid move from the lab to the mass market creates a massive opportunity for specialized operators including Aleen Inc. (CSE:ALEN), Moderna, Inc. (NASDAQ:MRNA), GE HealthCare (NASDAQ:GEHC), CeriBell, Inc. (NASDAQ:CBLL), and Palantir Te

GE HealthCare and Mayo Clinic launch GEMINI-RT, a strategic initiative to personalize radiation therapy by integrating imaging, AI, and patient monitoring across the cancer care continuum. The collaboration focuses on four pillars, automation, predictive oncology, multi-modal therapies, and outpatient monitoring, with the aim to enhance clinical outcomes, reduce clinician burnout, and accelerate innovation in radiation oncology. GE HealthCare (NASDAQ:GEHC) and Mayo Clinic today announced the GE HealthCare-Mayo Clinic Initiative in Radiation Therapy, known as GEMINI-RT, an ambitious new collaboration that aims to transform personalized radiation therapy and cancer care. Building on deca

Multi-year collaboration enables advanced diagnostic imaging and center of excellence in imaging sciences department across PET/CT, SPECT/CT, CT, MRI, and ultrasound. In-house production of radiopharmaceutical tracers helps enable precision medicine and theranostics program. Full standardization of patient monitoring across health system supports operational efficiency and consistent care for patients. University of Rochester Medical Center (URMC) and GE HealthCare (NASDAQ:GEHC) announce a Care Alliance to build advanced capabilities across URMC's footprint in upstate New York, including a center of excellence in its Imaging Sciences department, the addition of diagnostic tracer prod

NVIDIA technology is now integrated into several of GE HealthCare's new imaging solutions, including Photonova Spectra1, SIGNA Sprint with Freelium2, SIGNA Bolt3, Vivid Pioneer, and Pristina Recon DL. At RSNA 2025, GE HealthCare is also gathering feedback on early-stage exploratory workflow concepts4 within ultrasound and X-ray that incorporate autonomous technologies for continued research and development. At the Radiological Society of North America (RSNA) 2025 Annual Meeting, GE HealthCare (NASDAQ:GEHC) is showcasing several innovations brought to life through an expanded collaboration with NVIDIA. This collaboration underscores GE HealthCare's ongoing commitment to integrating adva

Compact, cable-free C-arm aims to maximize space and movement and allow greater flexibility and accessibility for everyday performance Patient-centric design featuring lateral wide-bore cone beam computed tomography with the goal of enhancing image quality to accommodate a range of patients and procedures for more inclusive care Built to empower clinicians with a future-ready environment aimed to provide enhanced efficiency and versatility, enabling improved patient outcomes GE HealthCare (NASDAQ:GEHC) today unveiled the Allia™ Moveoi, an image guiding solution designed to enhance mobility and flexibility and redefine the way clinicians deliver care in the interventional suite. This

The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the care journey across smart devices and drugs throughout disease states enabled by cloud and AI solutions. GE HealthCare has invested more than $3B in R&D since 2022, delivering an innovation renaissance across disease states to advance precision care. At this year's Radiological Society of North America's (RSNA) 2025 Annual Meeting, GE HealthCare (NASDAQ:GEHC) will showcase a wave of significant innovations grounded by its legacy and deep, global commitment to advancing precision care. For more than a century, GE HealthCare has stood at the intersec

SIGNA Bolt1, a new 3T MRI scanner, is designed with a next-gen gradient system engineered to support precision diagnostics, clinical efficiency, and advanced research capability. SIGNA Sprint with Freelium,2 a new sealed magnet MRI system, seeks to reimagine 1.5T MRI by combining a sustainable design with remarkable image quality, and operational autonomy to expand access to MR. Both new systems, 510(k) pending at the U.S. FDA, are powered by SIGNA One3, an ecosystem of AI-driven workflow solutions designed to reduce inefficiencies and support MRI exams from plan to scan and beyond. GE HealthCare (NASDAQ:GEHC) today announced the 510(k) submissions to the U.S. Food and Drug Administr

GE HealthCare has received FDA Premarket Authorization for Pristina Recon DL, an innovative 3D mammography reconstruction application. Powered by artificial intelligence (AI), Pristina Recon DL delivers sharper images with fewer artifacts, enhanced details, and greater consistency1 – helping clinicians make more confident diagnoses.  GE HealthCare (NASDAQ:GEHC) announced today that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. Powered by deep learning, Pristina Recon DL sets a new standard in image definition and sharpness. Breast cancer remains one of the most common cancers among women, with one in eigh

Genesis™ Radiology Workspace is designed to optimize radiology workflows, with a goal to empower diagnosticians to work from virtually anywhere with diagnostic accuracy, anchored by the Genesis™ View, the foundation of the solution that is intended to streamline radiologists' workflows. GE HealthCare (NASDAQ:GEHC) announced the introduction of Genesis™ Radiology Workspace, a next-generation solution designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision. At the center of this innovation is Genesis™ View, 510(k) pending2, a powerful new viewer designed to be a fast diagnostic, zero-footprint viewer – streamlining ra

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for mo

Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00

Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00

UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously

BTIG Research upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00

JP Morgan initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $90.00

Stifel initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00

Goldman initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $87.00

BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for mo

Revenue growth was 6% and Organic revenue growth* was 4% year-over year, driven by Europe, the Middle East and Africa (EMEA) and the U.S. Organic orders growth was 6% with growth across all segments Net income margin was 8.7%; Adjusted earnings before interest and taxes (EBIT) margin* was 14.8% Diluted earnings per share (EPS) were $0.98; Adjusted EPS* was $1.07 Cash flow from operating activities was $593 million; Free cash flow* was $483 million Excluding tariff impacts, margin and EPS would have exceeded prior year Raises the lower end of full-year 2025 Adjusted EPS* guidance range and reaffirms all other metrics GE HealthCare (NASDAQ:GEHC) today reported fina

GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical te

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025 payable on November 14, 2025 to all shareholders of record as of October 24, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for

Revenue growth was 3% year-over-year; Organic revenue growth* was 2% Net income margin was 9.7% versus 8.9% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 14.6% versus 15.3% Diluted earnings per share (EPS) were $1.06 versus $0.93 for the prior year; Adjusted EPS* was $1.06 versus $1.00 Cash flow from operating activities was $94 million versus $(119) million for the prior year; Free cash flow* was $7 million versus $(182) million Raises full-year 2025 guidance GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2025. GE HealthCare President and CEO Peter Arduini said, "We were pleas

GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more

Revenue growth was 3% year-over-year; Organic revenue growth* was 4% Net income margin was 11.8% versus 8.0% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.0% versus 14.7% Diluted earnings per share (EPS) were $1.23 versus $0.81 for the prior year; Adjusted EPS* was $1.01 versus $0.90 Cash flow from operating activities was $250 million versus $419 million for the prior year; Free cash flow* was $98 million versus $274 million Updates full-year 2025 guidance Board of Directors authorizes a $1 billion share repurchase program GE HealthCare (NASDAQ:GEHC) today reported financial results for the first quarter ended March 31, 2025. GE He

GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2025 payable on May 15, 2025 to all shareholders of record as of April 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than